https://orcid.org/0000-0001-6566-6450
References
- Petta I, Dejager L, Ballegeer M, et al. The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases. Microbiol Mol Biol Rev. 2016;80(2):495–522.
- Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2015;22(1-2):20–32.
- Kervoëlen C, Ménoret E, Gomez-Bougie P, et al. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. Oncotarget. 2015;6(29):26922–26934.
- Roberts A, Trapnell C, Donaghey J, et al. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 2011;12(3):R22.
- Heuck CJ, Szymonifka J, Hansen E, et al. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clin Cancer Res. 2012;18(19):5499–5506.
- Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
- Chen D, Zhou D, Xu J, et al. Prognostic value of 1q21 gain in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(3):e159–e164.
- Liu Y, Xu J, Choi HH, et al. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 2018;9(1):4718
- Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–e65.
- Merz M, Hielscher T, Seckinger A, et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am J Hematol. 2016;91(11):E473–E477.
- Abramova TV, Obukhova TN, Mendeleeva LP, et al. [Prognostic value of 1q21 amplification in multiple myeloma]. Ter Arkh. 2017;89(7):32–38.
- Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48(7):624–636.
- Lyu J, Song Z, Chen J, et al. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. J Pathol. 2018;244(3):358–366.
- Borsi E-C, Bucur A, Oncu CP, et al. First line therapy in multiple myeloma: VAD vs bortezomib –dexamethasone. Rev Chim. 2019;70(3):1017–1022.
- Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105(1):358–360.